NGM Bio Announces New Clinical Data from Ongoing Trial of NGM707 in Advanced Solid Tumors and Outlines Evolved Strategy for Aldafermin and NGM120 to Focus on Rare Conditions with Significant Unmet Need
Encouraging findings in heavily pretreated patients in multiple solid tumor indications, including MSS colorectal cancer , in ongoing Phase 1 Part 1b study evaluating NGM707, a dual ILT2/ILT4...
Source: marketscreener.com